Please login to the form below
Namenda
This page shows the latest Namenda news and features for those working in and with pharma, biotech and healthcare.
Forest said to be interested in $3bn Aptalis acquisition
US for former blockbuster antidepressant Lexapro (escitalopram), as well as generic competition from 2015 for Alzheimer's disease therapy Namenda (memantine). ... With Lexapro and Namenda accounting for more than three quarters of company turnover at
Latest news
-
Lundbeck and Otsuka take Alzheimer's drug into phase III
Regardless, it has been 10 years since the last new Alzheimer's treatment reached the market - Lundbeck's glutamate (NMDA) antagonist Ebixa (memantine), which is sold as Namenda by Forest Labs
-
Forest's net income down for Q3
He said: "We have been working diligently for the past seven years to build a solid product development pipeline that will more than replace the loss of Lexapro and Namenda following
-
Forest Laboratories earnings rise
Lexapro (escitalopram) and its Alzheimer's drug Namenda (memantine) lose their patent protection in the coming years. . ... expiration for both Lexapro in 2012 and Namenda in 2015 and provide growth," he said.
-
Lifting the fog
Additionally, a patch formulation of donepezil is in development. Also approved for the treatment of moderate-to-severe AD is memantine (Namenda, Forest Laboratories), which was the first NMDA receptor antagonist
-
Forest Labs earnings fall in Q2
revenues lost due to patent expiration for Lexapro in 2012 and [the Alzheimer's drug] Namenda (memantine) in 2015.".
Lundbeck and Otsuka take Alzheimer's drug into phase III
More from news
Approximately 0 fully matching, plus 13 partially matching documents found.
Latest Intelligence
-
Pharma deals during January 2014
Not disclosed. Adamas. Forest. Completion of studies for the NDA of a fixed dosed combination of Namenda and donepezil, Forest has exclusive US commercialisation rights.
-
Pharma deals during November 2012
Development / commercialisation. Fixed dose combination of Namenda and donepezil for AD.
Pharma deals during January 2014
More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- Medical Writer, Women’s health, Medical Communications agency, h...
-
Highly competitive salary
-
Senior Account Manager
-
Competitive salary offered
-
Omnichannel Strategy Consultant
-
Competitive Salary
- Results of AstraZeneca’s TACKLE phase 3 trial show antibody combination reduces risk of severe COVID-19 or death
- Merck’s anti-COVID drug molnupiravir moves to phase 3 for prevention
- Data shows patients treated with Biogen's MS therapies mount an effective antibody response to COVID-19 vaccination
- US demand for COVID-19 antibody treatments rising fast
- Assessing the value of interim analyses in clinical trials
- Bristol Myers Squibb announces data on Zeposia from DAYBREAK study in MS
- FDA accepts Regeneron’s REGEN-COV for priority review for treatment of COVID-19
- New data shows Roche's Enspryng significantly reduces neuromyelitis optica spectrum disorder relapses
- Beyond yoga and smoothies – providing real support for employee well-being
- Driving Healthcare Decisions with Natural Language Processing
- FDA approves Eli Lilly’s Verzenio in high risk early breast cancer
- Bristol Myers Squibb announces data on Zeposia from DAYBREAK study in MS
- Merck’s anti-COVID drug molnupiravir moves to phase 3 for prevention
- Novo Nordisk settles US insulin pricing dispute for $100m
- Starting a career in medical communications – experiences from the Nucleus Academy (part 2)
- Lynparza significantly delays disease progression as first-line treatment in prostate cancer
- Mylan completes acquisition of Merck's generic unit
- Celebrating the Communiqué Awards 2021
PMHub
Life Healthcare Communications
Life is a creative communications agency offering multi-channel solutions for the healthcare industry. We use a storytelling approach to turn...
Latest intelligence
- Committing time to making meaningful connections - top 5 tips
- Read the second blog of the series looking at key barriers to effective patient engagement in pharma...
- News:
- Senior Analytics Specialist joins Research Partnership...
- Digital technologies: Pharma’s answer to achieving net zero emissions?
- ...
